{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.5","upperLimit":"23.1","value":"16.1"}]}],"title":"PD-L1 <1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.5","upperLimit":"32.3","value":"23.8"}]}],"title":"PD-L1 >= 1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"21.8","value":"15.8"}]}],"title":"PD-L1 <5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.9","upperLimit":"39.5","value":"28.4"}]}],"title":"PD-L1 >=5%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. BIRC= blinded independent review committee PD-L1 expression level= membranous staining in greater than or equal to 5% and greater than or equal to 1% tumor cells. n = Number of participants in each category","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"OG000","title":"Nivolumab 3 mg/kg"}],"paramType":"NUMBER","populationDescription":"All treated participants. Treated participants from Japan enrolled after main enrollment period were excluded from primary efficacy analysis.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of objectively documented progression or the date of subsequent therapy, whichever occurs first (assessed up to 14 months)","title":"ORR Per BIRC Assessment by PD-L1 Expression Level","type":"PRIMARY","unitOfMeasure":"Percent of Participants"}